ROIV News and Press, Roivant Sciences Ltd. From 06/12/23

2023-06-12 03:54:39 ET Summary Roivant Sciences exhibits a strong financial outlook, backed by its substantial cash position, strategic acquisitions, and efficient R&D expense management. The company's innovative drug pipeline includes the breakthrough product VTAMA for atopic...

2023-05-26 22:25:40 ET Summary Roivant Sciences recently won approval for a topical cream, VTAMA, that looks set to achieve blockbuster (>$1bn per annum) sales. The company has several other highly promising late-stage clinical assets with blockbuster potential, and multiple da...

2023-05-16 07:39:45 ET Dermavant Sciences' Vtama cream met the main goal of achieving clearer skin in a second phase 3 trial to treat adults and pediatric patients down to 2 years old with moderate to severe atopic dermatitis (AD). The trial, dubbed ADORING 1, enrolled 407 children and ...

ADORING 1 met the primary and all secondary endpoints, consistent with the positive topline results from the Phase 3 ADORING 2 trial reported in March, marking Roivant’s 10 th consecutive positive Phase 3 study since 2019 45.4% of subjects receiving VTAMA achieved the primary end...

2023-04-23 16:45:00 ET Last December, Pfizer (NYSE: PFE) essentially out-licensed its tumor necrosis factor-like ligand 1A (TL1A), PF-06480605 (now RVT-3101), to Roivant Sciences (NASDAQ: ROIV) by forming a new company with the precision drugmaker. Per the terms of the deal ...

2023-04-22 16:00:00 ET Treatments for ulcerative colitis (UC) are projected to reach $9.6B in eight major markets by 2031 driven by an increase in the patient population and new therapies coming to market. That's the assessment from data and analytics firm GlobalData, which sees a 2...

2023-04-20 16:29:19 ET Shares of Roivant Sciences (NASDAQ: ROIV) , a pharmaceutical company that specializes in smaller portfolio companies that it calls Vants, were up by 25.3% for the week, as of Thursday afternoon, according to data provided by S&P Global Market Intelli...

2023-04-17 13:55:29 ET Biopharmaceutical stocks were trending higher across the board Monday morning, thanks to Merck 's (NYSE: MRK) nearly $11 billion buyout offer for Prometheus Biosciences (NASDAQ: RXDX) . So far, some of the day's biggest winners have been the cancer...

2023-04-17 08:21:00 ET CNS Pharmaceuticals ( CNSP ) +72% . Presto Automation ( PRST ) +55% . Prometheus Biosciences ( RXDX ) +70% soars 70%, Merck dips after ~$11B buyout deal. Dragonfly Energy  ( DFLI ) +49% . Kiromic BioPharma ( ...

2023-04-11 14:35:18 ET On Tuesday, a U.S. appeals court sided with Moderna ( NASDAQ: MRNA ) in a years-long patent dispute between the biotech and Arbutus ( NASDAQ: ABUS ) over messenger-RNA-based COVID vaccine technology. A three-judge panel at the U.S. Court of Appeals...